These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37226319)

  • 1. Reprogramming of Acute Myeloid Leukemia Patients Cells: Harboring Cancer Mutations Requires Targeting of AML Hierarchy.
    Golubeva D; Porras DP; Doyle M; Reid JC; Tanasijevic B; Boyd AL; Vojnits K; Elrafie A; Qiao A; Bhatia M
    Stem Cells Transl Med; 2023 Jun; 12(6):334-354. PubMed ID: 37226319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.
    Salci KR; Lee JH; Laronde S; Dingwall S; Kushwah R; Fiebig-Comyn A; Leber B; Foley R; Dal Cin A; Bhatia M
    Stem Cells; 2015 Jun; 33(6):1839-49. PubMed ID: 25764124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations.
    Lee JH; Salci KR; Reid JC; Orlando L; Tanasijevic B; Shapovalova Z; Bhatia M
    Stem Cells; 2017 Sep; 35(9):2095-2102. PubMed ID: 28758276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling leukemia with pediatric acute leukemia patient-derived iPSCs.
    Li T; Zhang Y; Li Y; Wang X; Bao W; Huang J; Ma Y; Li S; Wang S; Yang Y; Liu Y; Gao Y; Feng H; Li Y
    Stem Cell Res; 2021 Jul; 54():102404. PubMed ID: 34111697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia.
    Kotini AG; Carcamo S; Cruz-Rodriguez N; Olszewska M; Wang T; Demircioglu D; Chang CJ; Bernard E; Chao MP; Majeti R; Luo H; Kharas MG; Hasson D; Papapetrou EP
    Blood Cancer Discov; 2023 Jul; 4(4):318-335. PubMed ID: 37067914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells.
    Deslauriers AG; Kotini AG; Papapetrou EP
    Methods Mol Biol; 2021; 2185():411-422. PubMed ID: 33165864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation.
    Hoffmann D; Göhring G; Heuser M; Ganser A; Schambach A; Morgan MA
    Stem Cells; 2016 Mar; 34(3):797-9. PubMed ID: 26388310
    [No Abstract]   [Full Text] [Related]  

  • 8. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
    Chao MP; Gentles AJ; Chatterjee S; Lan F; Reinisch A; Corces MR; Xavy S; Shen J; Haag D; Chanda S; Sinha R; Morganti RM; Nishimura T; Ameen M; Wu H; Wernig M; Wu JC; Majeti R
    Cell Stem Cell; 2017 Mar; 20(3):329-344.e7. PubMed ID: 28089908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells.
    Ohmine S; Dietz AB; Deeds MC; Hartjes KA; Miller DR; Thatava T; Sakuma T; Kudva YC; Ikeda Y
    Stem Cell Res Ther; 2011 Nov; 2(6):46. PubMed ID: 22088171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia.
    Chiew MY; Boo NY; Voon K; Cheong SK; Leong PP
    Leuk Lymphoma; 2017 Jan; 58(1):162-170. PubMed ID: 27185517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.
    Kotini AG; Chang CJ; Chow A; Yuan H; Ho TC; Wang T; Vora S; Solovyov A; Husser C; Olszewska M; Teruya-Feldstein J; Perumal D; Klimek VM; Spyridonidis A; Rampal RK; Silverman L; Reddy EP; Papaemmanuil E; Parekh S; Greenbaum BD; Leslie CS; Kharas MG; Papapetrou EP
    Cell Stem Cell; 2017 Mar; 20(3):315-328.e7. PubMed ID: 28215825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iPSC Models of Leukemia Come of Age.
    Doulatov S
    Blood Cancer Discov; 2023 Jul; 4(4):252-253. PubMed ID: 37067903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional genomic approaches in acute myeloid leukemia: Insights into disease models and the therapeutic potential of reprogramming.
    Patel SA
    Cancer Lett; 2022 May; 533():215579. PubMed ID: 35124146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two iPSC lines generated from the bone marrow of a relapsed/refractory AML patient display normal karyotypes and myeloid differentiation potential.
    Yamasaki AE; King NE; Matsui H; Jepsen K; Panopoulos AD
    Stem Cell Res; 2019 Dec; 41():101587. PubMed ID: 31739201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An induced pluripotent stem cell t(7;12)(q36;p13) acute myeloid leukemia model shows high expression of MNX1 and a block in differentiation of the erythroid and megakaryocytic lineages.
    Nilsson T; Waraky A; Östlund A; Li S; Staffas A; Asp J; Fogelstrand L; Abrahamsson J; Palmqvist L
    Int J Cancer; 2022 Sep; 151(5):770-782. PubMed ID: 35583991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage.
    Sridhar A; Ohlemacher SK; Langer KB; Meyer JS
    Stem Cells Transl Med; 2016 Apr; 5(4):417-26. PubMed ID: 26933039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studying leukemia stem cell properties and vulnerabilities with human iPSCs.
    Spyrou N; Papapetrou EP
    Stem Cell Res; 2020 Dec; 50():102117. PubMed ID: 33388708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies.
    Tatwavedi D; Pellagatti A; Boultwood J
    Adv Biol Regul; 2024 Jan; 91():100993. PubMed ID: 37827894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.